uniQure N.V. Finite-Lived Intangible Asset, Expected Amortization, Year Three
uniQure N.V. (QURE) had Finite-Lived Intangible Asset, Expected Amortization, Year Three of $138.00 thousand as of 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Notes › Goodwill and Other › Intangible Asset, Finite-Lived, after Accumulated Amortization, Estimated Amortization Expense, Fiscal Year Maturity
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree · last filed 2026-03-02
- 2025-12-31: Finite-Lived Intangible Asset, Expected Amortization, Year Three $138.00K.
- 2024-12-31: Finite-Lived Intangible Asset, Expected Amortization, Year Three $3.23M.
- 2016-12-31: Finite-Lived Intangible Asset, Expected Amortization, Year Three $533.00K.
| Period end | Finite-Lived Intangible Asset, Expected Amortization, Year Three |
|---|---|
| 2025-12-31 | $138.00K 10-K · filed 2026-03-02 |
| 2024-12-31 | $3.23M 10-K · filed 2025-02-27 |
| 2016-12-31 | $533.00K 10-K · filed 2017-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |